REACH: non-regulatory announcement
Nuformix plc
("Nuformix", the "Company" or the "Group")
Initiation of research by Allenby Capital
The research is available on the Allenby Capital website here:
Enquiries:
|
Nuformix plc Dr Anne Brindley, CEO Fleur Wood, Investor Relations |
+44 (0)1223 627222
|
|
Allenby Capital Limited Tim Sohal / Matt Butlin (Sales and Corporate Broking) Nick Athanas / George Payne (Corporate Finance)
|
+44 (0)203 328 5656 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.
For more information, please visit www.nuformix.com.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.